Europe — EMA
Glypvilo
Glypvilo (vildagliptin) is an oral DPP‑4 inhibitor used in the EU for type 2 diabetes management; learn uses, side effects, precautions, and drug interactions.
Request sourcing
What is Vildagliptin?
Glypvilo is a prescription medication that contains the active ingredient vildagliptin, supplied as oral tablets (strength not specified). It belongs to the dipeptidyl peptidase‑4 (DPP‑4) inhibitor class and is marketed in the European Union for the management of type 2 diabetes mellitus.
What is Vildagliptin used for?
Glypvilo is indicated for the treatment of adults with type 2 diabetes mellitus, typically as part of a comprehensive diabetes management plan. It may be used alone or in combination with other antidiabetic agents.
- Improves glycemic control when added to diet and exercise. - Can be combined with metformin for enhanced effect. - May be used with sulfonylureas in patients not achieving target glucose levels. - Suitable for patients who require an oral DPP‑4 inhibitor. - Often prescribed when other oral agents are insufficient.
What are the side effects of Vildagliptin?
Side effects of Glypvilo vary in frequency and severity. Patients should be aware of both common and serious reactions.
Common: - Upper respiratory tract infection - Headache - Dizziness - Nausea - Diarrhea - Skin rash
Serious: - Severe allergic reactions (anaphylaxis, angioedema) - Pancreatitis symptoms (persistent abdominal pain) - Hepatotoxicity (elevated liver enzymes) - Severe hypoglycemia when combined with insulin or sulfonylureas
What precautions apply to Vildagliptin?
Before starting Glypvilo, certain health considerations should be reviewed to ensure safe use.
- Assess renal function; dose adjustment may be needed in impairment. - Monitor liver enzymes periodically during therapy. - Use caution in patients with a history of pancreatitis. - Evaluate for potential hypersensitivity reactions. - Educate patients on recognizing signs of hypoglycemia, especially when used with insulin or sulfonylureas. - Discuss pregnancy and lactation status with a healthcare professional.
What does Vildagliptin interact with?
Glypvilo can interact with several drug classes, requiring attention to avoid adverse effects.
Avoid: - Strong CYP3A4 inhibitors (e.g., ketoconazole) that may increase vildagliptin exposure. - Concurrent use with other DPP‑4 inhibitors.
Use with caution: - Insulin or sulfonylureas (risk of hypoglycemia). - Diuretics that may affect renal clearance. - NSAIDs that could impact renal function. - Rifampin (possible reduction in efficacy).
Frequently asked questions
What is the mechanism of action of Glypvilo (vildagliptin)?+
Can Glypvilo be used as a first‑line therapy for type 2 diabetes?+
Is dose adjustment required for Glypvilo in patients with kidney disease?+
What are common side effects of Glypvilo?+
What serious adverse reactions should patients be aware of while taking Glypvilo?+
Should Glypvilo be taken with food?+
Can Glypvilo be combined with metformin?+
What monitoring is recommended during Glypvilo therapy?+
Is Glypvilo safe during pregnancy or breastfeeding?+
What should I do if I miss a dose of Glypvilo?+
Are there any foods or beverages that should be avoided while taking Glypvilo?+
How does Glypvilo differ from other DPP‑4 inhibitors?+
Product details
Related products

A
Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

A
Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

A
Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

A
Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo